Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.

ABSTRACT: Randomized controlled trials (RCTs) are an important mode of access to treatments for patients with inflammatory bowel diseases (IBDs) (eg, Crohn's disease [CD], ulcerative colitis [UC]), and a critical step in the regulatory process toward the approval of new therapies. Prior studies examining disparities in RCT participation for patients with IBD have importantly focused on racial and age-related disparities.^1,2 Lack of geographic access to trials may be an important barrier to participation and a source of inequity. The aim of our study was to geographically map access to phase 3 clinical trials in IBD within the United States, and identify the impact of rural residence and socioeconomic status on access to trials.

SUBMITTER: Boyd T 

PROVIDER: S-EPMC10858973 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature